Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification, and Patient Selection

Program Overview

Given the rapidly evolving field of cardiac stress testing with respect to new risk stratification algorithms, new agents, and new assessment methods, it is difficult for physicians to remain up to date on the latest research and the benefits and risks of different testing modalities. This CME activity provides an overview on the indications and guidelines for testing for coronary heart disease. A panel of experts discuss evidence-based data and exercise practical implications for clinical decision-making. This educational intervention will bring clinicians a current understanding of patient-centered cardiovascular imaging to improve the individualized management of patients with suspected coronary heart disease.

Target Audience

Cardiologists, internists, and physicians who care for patients with coronary heart disease.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the factors and guidelines for risk stratification and patient selection when ordering a pharmacological cardiac stress test, including the pre-operative assessment.
  2. Analyze recent clinical trial data concerning the application of pharmacologic agents used to induce cardiac stress, as well as state-of-the-art diagnostic imaging techniques.
  3. Improve communication between internists and cardiologists to order the right cardiac stress test for the right patients.
  4. Implement patient education and communication strategies that involve the patient in the decision-making process and prepare the patient for cardiac stress testing


Ron Blankstein, MD
Non-invasive Cardiovascular Imaging Training Program
Cardiovascular Division & Department of Radiology
Brigham and Women's Hospital
Assistant Professor
Medicine and Radiology
Harvard Medical School
Boston, MA

Christopher Cannon, MD
Senior Physician
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School                                      
Boston, MA

James Udelson, MD
Chief, Division of Cardiology
Director, Nuclear Cardiology Laboratory
Professor, Tufts University School of Medicine
Boston, MA

Disclosure Statements

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With

Ron Blankstein, MD

Has disclosed no relevant financial relationships.

Christopher Cannon, MD

Research Grant: Accumetrics; AstraZeneca; Boehringer-Ingelheim; CSL Behring; Essentialis, Inc; GlaxoSmithKline; Merck; Regeneron Pharmaceuticals, Inc.; Sanofi-avantis; Takeda Pharmaceuticals North America, Inc.

Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Bristol-Myers Squibb; LipimetiX; Pfizer Inc.

James Udelson, MD

Has disclosed no relevant financial relationships.

Non-faculty: Timothy Hayes, MD, PhD; Esther Polgar; Kristen Scollon; Sandy Breslow; Jill McNair; and Tania Dickson, PhD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Journal Distribution

This enduring material has been peer-reviewed and approved by The American Journal of Medicine and The American Journal of Cardiology.

Accreditation Statement

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Course Open Date: May 20, 2014 | Course Expiration Date: May 19, 2015

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Astellas Pharma US, Inc.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Astellas Pharma US, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

Privacy Policy

Course details

  • Course opens: May 20, 2014
  • Course expires: May 19, 2017

Please log in or register to take this Course.